

Lifetime Probability of Developing or Dying from Cancer, US, 2018-2019, 2021

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
All sites^a	39.9	3	18.9	5	39.0	3	17.1	6
Brain & ONS	0.7	154	0.5	195	0.5	192	0.4	245
Breast	0.1	755	<0.1	3,641	13.1	8	2.5	40
Colorectal	4.1	24	1.7	61	3.8	26	1.5	65
Esophagus	0.8	132	0.6	157	0.2	437	0.2	547
Hodgkin lymphoma	0.2	446	<0.1	2,964	0.2	536	<0.1	3,825
Kidney & renal pelvis	2.2	45	0.5	187	1.3	75	0.3	332
Larynx	0.5	211	0.2	621	0.1	875	<0.1	2,650
Leukemia	1.8	55	0.9	116	1.3	77	0.6	161
Liver & intrahepatic bile duct	1.5	68	1.1	93	0.7	143	0.6	163
Lung & bronchus	5.8	17	4.0	25	5.6	18	3.6	28
Melanoma of skin ^b	3.5	29	0.4	247	2.5	40	0.2	472
Myeloma	0.9	108	0.4	233	0.8	133	0.3	290
Non-Hodgkin lymphoma	2.3	44	0.7	134	1.9	54	0.6	174
Oral cavity & pharynx	1.6	61	0.4	245	0.7	139	0.2	543
Ovary	--	--	--	--	1.1	89	0.8	126
Pancreas	1.7	60	1.4	72	1.7	60	1.4	72
Prostate	12.8	8	2.4	42	--	--	--	--
Stomach	1.0	104	0.4	227	0.7	153	0.3	321
Testis	0.4	248	<0.1	4,912	--	--	--	--
Thyroid	0.6	160	0.1	1,693	1.7	59	0.1	1,289
Urinary bladder ^c	3.4	29	0.8	118	1.1	93	0.3	311
Uterine cervix	--	--	--	--	0.6	156	0.2	469
Uterine corpus	--	--	--	--	3.1	32	0.7	145

^aExcludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

^bStatistics are for non-Hispanic Whites.

^cIncludes invasive and in situ cancer cases.

Data source: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.9.0, National Cancer Institute, 2024.

